z-logo
open-access-imgOpen Access
Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)
Author(s) -
JeanMichel Molina,
Sébastien Gallien,
MarieLaure Chaix,
El Mountacer El Abbassi,
Isabelle Madelaine,
Christine Katlama,
Nadia Valin,
Pierre Delobel,
Kristell Desseaux,
Gilles Peytavin,
Juliette Saillard,
F. Raffi,
Sylvie Chevret,
Diane Ponscarme,
C. Lascoux,
Pierre Marie Girard,
A. Rami,
Yazdan Yazdanpanah,
Anne Simon,
Roland Tubiana,
Claudine Duvivier,
Vincent Jeantils,
D Loreillard,
Isabelle PoizotMartin,
Louis Bernard,
Guillaume Gras,
Clotilde Allavena,
C. Bernaud,
Sabelline Bouchez,
Nancy Hall,
Véronique Reliquet,
P. de Truchis,
Isabelle Charreau,
L Bocquet,
Vincent Le Moing,
G Point,
Pierre Tattevin,
S. Couffin-Cadiergues,
Alpha Diallo,
Séverine Gibowski
Publication year - 2018
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dky181
Subject(s) - darunavir , ritonavir , open label , medicine , human immunodeficiency virus (hiv) , virology , pharmacology , antiretroviral therapy , randomized controlled trial , viral load
To assess whether low-dose ritonavir-boosted darunavir (darunavir/r) in combination with two NRTIs could maintain virological suppression in patients on a standard regimen of darunavir/r + two NRTIs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom